Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Solid Biosciences Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Solid Biosciences Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Smith Ian F | Director | 138,145 | Jul 7, 2026 | 5 |
| Edelman Joseph | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Advisors LLC | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Life Sciences Master Fund Ltd | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Nagendran Sukumar | Director | – | Jun 11, 2026 | 1 |
| Freed Martin I | Director | – | Jun 11, 2026 | 1 |
| Stone Adam Leo | Director | – | Jun 11, 2026 | 1 |
| Ganot Ilan | Director | 27,474Indirect | Jun 11, 2026 | 7 |
| Sullivan Lynne Marie | Director | – | Jun 11, 2026 | 1 |
| Keresty Georgia | Director | – | Jun 11, 2026 | 1 |
| Kahn Clare | Director | 2,960 | Jun 11, 2026 | 1 |
| Howton David T | Chief Operating Officer | 105,077 | Apr 21, 2026 | 5 |
| Cumbo Alexander | President and CEO | 235,405 | Apr 21, 2026 | 5 |
| Tan Kevin | CFO & Treasurer | 99,422 | Apr 21, 2026 | 5 |
| Hanrahan Jessie | Chief Regulatory Officer | 74,318 | Apr 21, 2026 | 5 |
| Herzich Paul | Chief Technology Officer | 72,638 | Apr 21, 2026 | 5 |
| Brooks Gabriel | Chief Medical Officer | 89,466 | Apr 21, 2026 | 5 |
| BCIP Life Sciences Associates, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS SB Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities GP, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Perceptive Xontogeny Venture Fund, LP | Director, 10% Owner | 11,833,539Indirect | Feb 21, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Kolchinsky Peter | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Shah Rajeev M. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Atchinson Robert | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Gross Phillip | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Adage Capital Management, L.P. | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Marlowe Jennifer | CSO | 6,998 | Feb 16, 2024 | 0 |
| RA Capital Nexus Fund, L.P. | Director, 10% Owner | 4,192,216Indirect | Jan 12, 2024 | 0 |
| Koppel Adam | Director, 10% Owner | 4,034,582Indirect | Jan 12, 2024 | 0 |
| Morris Carl Ashley | Chief Scientific Officer | 19,760 | Jan 31, 2023 | 0 |
| Huffines Robert Luther | Director | – | Dec 15, 2022 | 0 |
| Perceptive Venture Advisors, LLC | Director, 10% Owner | 73,107Indirect | Dec 6, 2022 | 0 |
| Brennan Erin Powers | Chief Legal Officer, Secretary | – | May 4, 2022 | 0 |
| Schneider Joel Solomon Zev | Chief Operating Officer | 236,270 | Mar 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 (view filing) | Jun 7 | 4 days | Kahn ClareDirector | PPurchase | +1.10K | $7.67 | +$8.44K | New position1.10K after | |
| May 6, 2024 (view filing) | May 2 | 4 days | Ganot IlanDirector | SSale | −462 | $10.33 | −$4.77K | −4.6%9.51K after | |
| Jan 30, 2024 (view filing) | Jan 29 | 1 day | Ganot IlanDirector | SSale | −139 | $7.99 | −$1.11K | −1.6%8.42K after | |
| Jan 12, 2024 (view filing)5:15 PM ET | Jan 11 | 1 day | Edelman Joseph and 3 othersDirector, 10% Owner | PPurchase | +3.41M | $5.53 | +$18.9M | +99.6%6.83M after | |
| Jan 12, 2024 (view filing)5:01 PM ET | Jan 11 | 1 day | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +904.2K | $5.53 | +$5.00M | +27.5%4.19M after | |
| Jan 11, 2024 (view filing) | Jan 9 | 2 days | Tan KevinCFO & Treasurer | SSale | −3.94K | $8.20 | −$32.3K | −29.7%9.31K after | |
| Jan 5, 2024 (view filing) | Jan 3 | 2 days | Ganot IlanDirector | SSale | −1.14K | $5.30 | −$6.05K | −12.3%8.17K after | |
| Dec 5, 2023 (view filing) | Dec 4 | 1 day | Cumbo AlexanderPresident and CEO | SSale | −11.8K | $2.77 | −$32.6K | −40.3%17.4K after | |
| Dec 5, 2023 (view filing) | Dec 4 | 1 day | Howton David TChief Operating Officer | SSale | −5.37K | $2.78 | −$14.9K | −41.1%7.68K after | |
| Dec 5, 2023 (view filing) | Dec 4 | 1 day | Herzich PaulChief Technology Officer | SSale | −2.97K | $2.77 | −$8.22K | −41.0%4.27K after | |
| Dec 5, 2023 (view filing) | Dec 4 | 1 day | Hanrahan JessieChief Regulatory Officer | SSale | −4.88K | $2.78 | −$13.6K | −41.1%6.98K after | |
| Dec 5, 2023 (view filing) | Dec 4 | 1 day | Marlowe JenniferCSO | SSale | −4.89K | $2.77 | −$13.5K | −41.1%7.00K after | |
| Jun 8, 2023 (view filing) | May 2 | 37 daysLate | Ganot IlanDirector | SSale | −487 | $4.85 | −$2.36K | −10.5%4.15K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Morris Carl AshleyChief Scientific Officer | SSale | −441 | $7.49 | −$3.30K | −2.2%19.8K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Ganot IlanDirector | SSale | −141 | $7.49 | −$1.06K | −9.3%1.38K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Ganot IlanDirector | SSale | −1.38K | $7.49 | −$10.4K | −1.6%84.6K after | |
| Mar 15, 2022 (view filing) | Mar 14 | 1 day | Morris Carl AshleyChief Scientific Officer | SSale | −22.7K | $1.10 | −$24.9K | −8.2%255.2K after | 2 lots |
| Mar 15, 2022 (view filing) | Mar 14 | 1 day | Schneider Joel Solomon ZevChief Operating Officer | SSale | −30.5K | $1.10 | −$33.6K | −11.4%236.3K after | 2 lots |
| Mar 8, 2022 (view filing) | Feb 10 | 26 daysLate | Ganot IlanCEO & President | SSale | −463 | $1.12 | −$518.56 | −15.5%2.52K after |